Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
MIRMESCONDIDO, Calif.--(BUSINESS WIRE)--Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 (formerly ENT-3379), Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), in December, reported the initiation of the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS). MRM-3379 is an orally available, highly brain-penetrant, selective phosphodiestera
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM(NASDAQ:MIRM) FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study
MIRM(NASDAQ:MIRM) FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational oral IBAT inhibitor, for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis (PSC). The trial previously met its pre-specified efficacy and safety thresholds at the blinded interim analysis for dose selection conducted in 2024 and topline results are expected to be announced i
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
MIRMFOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRMFOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HC Wainwright & Co. Assumes Mirum Pharmaceuticals at Buy, Announces Price Target of $73
MIRMRaymond James Maintains Strong Buy on Mirum Pharmaceuticals, Raises Price Target to $77
MIRMBeyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock
MIRMJMP Securities Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $76
MIRMMirum Pharmaceuticals Raises FY2025 Sales Guidance from $420.00M-$435.00M to $435.00M-$450.00M vs $427.76M Est
MIRMMirum Pharmaceuticals Q1 EPS $(0.30) Beats $(0.32) Estimate, Sales $111.60M Beat $98.40M Estimate
MIRMPreview: Mirum Pharmaceuticals's Earnings
MIRMFDA Approves Mirum Pharma's Livmarli Tablet Formulation For Treatment Of Cholestatic Pruritus In Patients With Alagille Syndrome And Progressive Familial Intrahepatic Cholestasis
MIRMHC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $72
MIRMBaird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $55
MIRMMirum Pharmaceuticals Q4 2024 GAAP EPS $(0.49) Misses $(0.28) Estimate, Sales $99.430M Beat $96.606M Estimate
MIRMMirum Pharmaceuticals Sees FY25 Net Product Sales $420M-$435M Vs $425.523M Est.
MIRMMirum Pharmaceuticals Q4 Sales $99.430M Beat $96.606M Estimate
MIRMCitizens Capital Markets Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $74 Price Target
MIRMMirum's CTEXLI Tablets Receives FDA Approval For Treatment Of Cerebrotendinous Xanthomatosis
MIRMFDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol
MIRMMirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.
'FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, A Rare Lipid Storage Disease'
MIRMMirum Pharmaceuticals Projects $336M Sales Exceed 2024 Guidance; 2025 Sales Forecast $420M-$435M; VISTAS Study Enrollment For Volixibat In Primary Sclerosing Cholangitis Completing H2 2025, Topline Data Expected 2026
MIRMMirum Pharmaceuticals To Showcase Data From Its LIVMARLI And Volixibat Clinical Programs At AASLD's The Liver Meeting November 15-19, 2024
MIRMMirum Pharmaceuticals To Showcase LIVMARLI Data From Its ALGS And PFIC Programs At The NASPGHAN Annual Meeting
MIRMReported Saturday, Mirum Pharmaceuticals' LIVMARLI Data Presented At ESPGHAN, Featuring Key Findings On ALGS And PFIC
MIRMA Preview Of Mirum Pharmaceuticals's Earnings
MIRMMirum Pharmaceuticals (NASDAQ:MIRM) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Mirum Pharmaceuticals will report an earnings per share (EPS) of $-1.34.
